首页 | 本学科首页   官方微博 | 高级检索  
     

护心通络方通过干预CETP介导脂质代谢抗兔动脉粥样硬化的实验研究
引用本文:王华,何雄. 护心通络方通过干预CETP介导脂质代谢抗兔动脉粥样硬化的实验研究[J]. 天津医药, 2022, 50(8): 827-831. DOI: 10.11958/20212849
作者姓名:王华  何雄
作者单位:1湖南中医药大学第一附属医院机构办科(邮编410007)2湖南省药品审评与不良反应监测中心
基金项目:湖南省自然科学基金科卫联合项目(2020JJ8025);
摘    要:
目的 探究护心通络方通过调控胆固醇脂转运蛋白(CETP)抗兔动脉粥样硬化(AS)的效果及作用机制。方法 将40只雄性新西兰兔按照随机数字表法分为空白对照组、AS模型组、辛伐他汀组[0.33 mg/(kg·d)]、护心通络方组[0.34 g/(kg·d)],每组10只。空白对照组予普通饲料喂养22周,其他3组予高脂饲料喂...

关 键 词:动脉粥样硬化  胆固醇,HDL    护心通络方  胆固醇脂转运蛋白  ABCA1/apoA-I/LCAT通路
收稿时间:2021-12-26
修稿时间:2022-05-07

Experimental study of huxintongluo decoction on rabbit atherosclerosis by intervening CETP mediated lipid metabolism
WANG Hua,HE Xiong. Experimental study of huxintongluo decoction on rabbit atherosclerosis by intervening CETP mediated lipid metabolism[J]. Tianjin Medical Journal, 2022, 50(8): 827-831. DOI: 10.11958/20212849
Authors:WANG Hua  HE Xiong
Affiliation:1 Institutional Office of the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China
2 Hunan Center for Drug Evaluation and Adverse Reaction Monitoring
Abstract:
Objective To study the effect and mechanism of huxintongluo decoction on rabbit atherosclerosis (AS) by regulating cholesterol lipid transporter protein (CETP). Methods Forty male New Zealand rabbits were divided into the blank control group, the AS model group, the simvastatin group [0.33 mg/(kg·d)] and the huxintongluo group [0.34 g/(kg·d)] according to random number table method, with 10 rabbits in each group. The blank control group was fed ordinary diet for 22 weeks. The other three groups were fed with high fat diet for 14 weeks, and then different drug intervention was performed in groups for 8 weeks. Serum levels of high density lipoprotein (HDL-C), low density lipoprotein (LDL-C), total cholesterol (TC) and triglyceride (TG) were detected before the experiment, 14 and 22 weeks after administration. The animals were sacrificed at the end of the 22-week, the thoracic aorta was separated, and the pathological changes were observed by hematoxyl-eosin (HE) staining. The expression levels of ABCA1, apoA-I and LCAT in liver tissues were detected by fluorescence quantitative PCR and Western blot assay. Results There were no significant differences in serum levels of TC, TG, HDL-C and LDL-C before the experiment between the four groups (P>0.05). At week 14 of experiment, compared with the blank control group, serum levels of TC, TG and HDL-C were significantly increased in the other three groups, while the serum level of LDL-C was significantly decreased (P<0.05). At week 22 of experiment, compared with the AS model group, serum levels of TC, TG and LDL-C were significantly decreased in the other three groups, while serum level of HDL-C was significantly increased (P<0.05). Compared with the blank control group, the serum level of CETP increased in the AS model group. Compared with the AS model group, the serum level of CETP decreased in the simvastatin group and the huxintongluo group. Compared with the blank control group, ABCA1, apoA-I and LCAT mRNA and protein levels in liver tissues were decreased in the AS model group. Compared with the AS model group, mRNA and protein levels of ABCA1, apoA-I and LCAT were increased in the simvastatin group and the Huxintongluo group (P<0.05). Conclusion Huxintongluo decoction can activate ABCA1/apoA-I/LCAT pathway by reducing CETP level, ultimately improve HDL-C level and improve atherosclerosis in rabbits.
Keywords:atherosclerosis  cholesterol   HDL  rabbits  huxintongluo decoction  cholesterol lipid transporter  ABCA1/apoA-I/LCAT pathways  
点击此处可从《天津医药》浏览原始摘要信息
点击此处可从《天津医药》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号